Medication pen injector needle Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medication pen injector needle

hospitalija trgovina d.o.o. za trgovinu i usluge vojvodići 25 10431 novaki, sveta nedjelja -

DEKSMEDETOMIDIN PHARMIDEA 100 µg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

deksmedetomidin pharmidea 100 µg/1 ml koncentrat za rastvor za infuziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - deksmedetomidin - koncentrat za rastvor za infuziju - 100 µg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži 100 mikrograma deksmedetomidina (u obliku deksmedetomidinhidrohlorida)

Kalydeco Europska Unija - hrvatski - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Ngenla Europska Unija - hrvatski - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hipofize i ГИПОТАЛАМИЧЕСКИЕ hormoni i analozi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Humira Europska Unija - hrvatski - EMA (European Medicines Agency)

humira

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Orkambi Europska Unija - hrvatski - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - tablete orkambi rezultati za liječenje муковисцидоза (mv) kod bolesnika u dobi od 6 i više godina, koji su гомозиготами na mutacije f508del u genu cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Kaftrio Europska Unija - hrvatski - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Berlistar forte 40 mg/ml oralna suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

berlistar forte 40 mg/ml oralna suspenzija

berlin-chemie ag, glienicker weg 125, berlin, njemačka - ibuprofen - oralna suspenzija - 40 mg/ml - urbroj: 1 ml oralne suspenzije sadrži 40 mg ibuprofena

Olytabs 200 mg/30 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

olytabs 200 mg/30 mg filmom obložene tablete

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ibuprofenum, pseudoephedrinum - filmom obložena tableta - 200 mg + 30 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg ibuprofena i 30 mg pseudoefedrinklorida

IBUMAX 4 % 40 mg/1 mL oralna suspenzija Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ibumax 4 % 40 mg/1 ml oralna suspenzija

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - ibuprofen - oralna suspenzija - 40 mg/1 ml - 1 ml oralne suspenzije sadrži: 40 mg ibuprofena